2 227

Cited 22 times in

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.

 Sang Kyun Sohn  ;  Suk Joong Oh  ;  Byung Soo Kim  ;  Hun Mo Ryoo  ;  Joo Seop Chung  ;  Young Don Joo  ;  Soo Mee Bang  ;  Chul Won Jung  ;  Dong Hwan Kim  ;  Sung Soo Yoon  ;  Ho In Kim  ;  Hong Ghi Lee  ;  Jong Ho Won  ;  Yoo Hong Min  ;  June Won Cheong  ;  Joon Seong Park  ;  Ki Seong Eom  ;  Myung Soo Hyun  ;  Min Kyoung Kim  ;  Hawk Kim  ;  Moo Rim Park  ;  Jinny Park  ;  Chul Soo Kim  ;  Hyeoung Joon Kim  ;  Yeo Kyeoung Kim  ;  Eun Kyung Park  ;  Dae Young Zang  ;  Deog Yeon Jo  ;  Joon Ho Moon  ;  Seon Yang Park 
 LEUKEMIA & LYMPHOMA, Vol.52(6) : 1024-1029, 2011 
Journal Title
Issue Date
Adolescent ; Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/therapeutic use ; Benzamides ; Female ; Fusion Proteins, bcr-abl/genetics ; Humans ; Imatinib Mesylate ; Leukemia, Myeloid, Chronic-Phase/drug therapy* ; Leukemia, Myeloid, Chronic-Phase/genetics* ; Logistic Models ; Male ; Neutropenia/chemically induced ; Piperazines/blood ; Piperazines/pharmacokinetics ; Piperazines/therapeutic use* ; Prospective Studies ; Pyrimidines/blood ; Pyrimidines/pharmacokinetics ; Pyrimidines/therapeutic use* ; Reverse Transcriptase Polymerase Chain Reaction ; Thrombocytopenia/chemically induced ; Time Factors ; Transcription, Genetic/drug effects ; Treatment Outcome ; Young Adult
Chronic myeloid leukemia ; imatinib ; trough blood level ; cytogenetic response ; molecular response
To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard dose of IM. Eighty-seven newly diagnosed patients with CML-CP were prospectively enrolled. Seventy-eight patients (89.7%) showed an optimal response (complete or partial cytogenetic response) at 6 months. Trough IM levels were 1378 ± 725 ng/mL. When categorized into two groups, there was a statistically significant difference in numbers of patients with optimal and suboptimal responses at 6 months (group with  <1000: 80.6% vs. 19.4%;  ≥ 1000: 94.6% vs. 5.4%; p = 0.032), and in numbers of patients with early major molecular response (early-MMR) and without MMR at 6 months (group with  <1000: 3.2% vs. 96.8%;  ≥ 1000: 21.4% vs. 78.6%; p = 0.047). In conclusion, the incidence of optimal cytogenetic response or early-MMR in patients with CML-CP treated with IM for 6 months was significantly higher in those with a trough level of  ≥ 1000 compared with those with a level of <1000. Dose escalation of IM can be one option in patients with CML showing suboptimal response or resistance to the standard dose of IM, especially with low trough plasma IM levels (<1000 ng/mL).
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Min, Yoo Hong(민유홍) ORCID logo https://orcid.org/0000-0001-8542-9583
Cheong, June-Won(정준원) ORCID logo https://orcid.org/0000-0002-1744-0921
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.